Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 45% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
3 citing papers in PubMed, 4 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
15 authors at 3 institutions in 2 countries.
Jésica Pérez-GarcíaInstitute of Biomedical Research of Salamanca (IBSAL), SACYL-University of Salamanca-CSIC, 37007 Salamanca, Spain.ORCID 0000-0001-9224-2637
Abel Martel-MartelInstitute of Biomedical Research of Salamanca (IBSAL), SACYL-University of Salamanca-CSIC, 37007 Salamanca, Spain.ORCID 0000-0001-7857-5240
Paula García-VallésInstitute of Biomedical Research of Salamanca (IBSAL), SACYL-University of Salamanca-CSIC, 37007 Salamanca, Spain.ORCID 0000-0003-4574-8779
Luis A CorcheteInstitute of Molecular and Cellular Biology of Cancer (IBMCC), University of Salamanca-CSIC, 37007 Salamanca, Spain.ORCID 0000-0003-4577-8599
Juan L GarcíaInstitute of Biomedical Research of Salamanca (IBSAL), SACYL-University of Salamanca-CSIC, 37007 Salamanca, Spain.ORCID 0000-0002-2146-5726
Nerea Gestoso-UzalInstitute of Biomedical Research of Salamanca (IBSAL), SACYL-University of Salamanca-CSIC, 37007 Salamanca, Spain.
Rosario Vidal-TocinoInstitute of Biomedical Research of Salamanca (IBSAL), SACYL-University of Salamanca-CSIC, 37007 Salamanca, Spain.ORCID 0000-0002-0588-2001
Óscar BlancoInstitute of Biomedical Research of Salamanca (IBSAL), SACYL-University of Salamanca-CSIC, 37007 Salamanca, Spain.
Lucía MéndezInstitute of Biomedical Research of Salamanca (IBSAL), SACYL-University of Salamanca-CSIC, 37007 Salamanca, Spain.
Manuel Sánchez-MartínInstitute of Biomedical Research of Salamanca (IBSAL), SACYL-University of Salamanca-CSIC, 37007 Salamanca, Spain.ORCID 0000-0001-8370-1336
Manuel FuentesDepartment of Medicine and Cytometry General Service-Nucleus, CIBERONC, Cancer Research Centre (IBMCC/CSIC/USAL/IBSAL), 37007 Salamanca, Spain.ORCID 0000-0002-7305-3766
Ana B HerreroInstitute of Biomedical Research of Salamanca (IBSAL), SACYL-University of Salamanca-CSIC, 37007 Salamanca, Spain.ORCID 0000-0002-1414-6532
Andreana N HolowatyjDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA.ORCID 0000-0001-8001-8793
José PereaInstitute of Biomedical Research of Salamanca (IBSAL), SACYL-University of Salamanca-CSIC, 37007 Salamanca, Spain.ORCID 0000-0001-5522-8844
Rogelio González-SarmientoInstitute of Biomedical Research of Salamanca (IBSAL), SACYL-University of Salamanca-CSIC, 37007 Salamanca, Spain.ORCID 0000-0002-2726-6795
Universidad de Salamanca · ESInstituto de Investigación Biomédica de Salamanca · ESVanderbilt University Medical Center · US
Funding
Building Interdisciplinary Research Careers in Women's HealthK12HD043483 · NICHD · VANDERBILT UNIVERSITY MEDICAL CENTER · PI HARTMANN, KATHERINE E, MAJOR, AMY S · 2002 to 2023
$10.3M
Fundación Mutua Madrileña FMM20/001Instituto de Salud Carlos III PI20/01569Instituto de Salud Carlos III PI20/0974NICHD NIH HHS K12 HD043483
6 · The paper itself
Abstract
The incidence of early-onset colorectal cancer (EOCRC; age younger than 50 years) has been progressively increasing over the last decades globally, with causes unexplained. A distinct molecular feature of EOCRC is that compared with cases of late-onset colorectal cancer, in EOCRC cases, there is a higher incidence of
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.